The company plans to use the funds for general corporate purposes, including, together with cash on hand, to repay borrowings under its term loan facility.
For the three months ended April 30, the firm's revenues were $1.24 billion, flat with $1.24 billion in Q2 2019 but beating Wall Street analysts' average estimate of $1.21 billion.
The firm noted a disruption in global business in late March, as customers closed or restricted access to their facilities in an attempt to slow the spread of the coronavirus.
The deal is aimed at providing technologies, products, and services that will improve the standardization of pathology labs and accelerate accurate diagnoses.
The team anticipates launching its first clinical diagnostic assay, which will detect targeted, low-frequency genetic mutations in lung cancer, in 2021.
